Imunon Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Imunon has a total shareholder equity of $3.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.7M and $6.0M respectively.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$5.31m
Patrimonio netto	US$3.74m
Totale passività	US$5.95m
Totale attività	US$9.69m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: 0HUZ's short term assets ($7.6M) exceed its short term liabilities ($5.1M).

Passività a lungo termine: 0HUZ's short term assets ($7.6M) exceed its long term liabilities ($872.9K).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 0HUZ is debt free.

Riduzione del debito: 0HUZ has no debt compared to 5 years ago when its debt to equity ratio was 51%.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 0HUZ has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Previsione Cash Runway: 0HUZ is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.

Imunon Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon Receives Non-Compliance Notice From Nasdaq

Recent updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Financial position

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.59 loss per share (vs US$2.19 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane